Loading
Enara Bio
An Oxford company that looks for cancer-only markers hidden in parts of the genome usually ignored, and builds drugs that steer the immune system's T cells onto tumours carrying them. Its lead drug, ENA101, is still in laboratory testing for several solid tumours.
Also called: Enara Bio Limited
Overview
Enara Bio searches for what it calls Dark Antigen targets, cancer-specific peptides from non-canonical parts of the genome, using its EDAPT platform, and builds bispecific T-cell engagers on its EnTiCE platform. Its lead programme, ENA101, is a T-cell engager that recognises a DARKFOX peptide presented by HLA-A*03:01; the company says DARKFOX is encoded by an alternative open reading frame within FOXM1 and is found in NSCLC, upper GI, colorectal, breast, ovarian, head and neck, bladder and other cancers. Preclinical ENA101 data were presented orally at AACR in April 2026, and the pipeline page targets a CTA/IND in the fourth quarter of 2026. Boehringer Ingelheim has licensed multiple Dark Antigen targets from Enara and is developing vaccines for non-small cell lung cancer from them. The company names RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors as backers.
Notes
- Founding year 2016 is the Companies House incorporation date of Enara Bio Limited (company 10469748).
- No clinical trial yet; ENA101 is preclinical, so no product record drafted.
- FOXM1 is not a target in OnCo, and DARKFOX is a FOXM1 alternative reading frame, not FOXM1 itself; targets left empty.
- Cancer ids left empty because ENA101 is described as pan-cancer and has no trial.
Connected
6Similar pages
- CompanyNormunity
Shares Pfizer Ventures, Samsara BioCapital, T-cell engagers (bispecific).
- CompanyAlpheus Medical
Shares SV Health Investors, Samsara BioCapital.
- CompanyAlpha-9 Oncology
Shares Samsara BioCapital, RA Capital Management.
- CompanyTriana Biomedicines
Shares Pfizer Ventures, RA Capital Management.
- CompanyEnlaza Therapeutics
- CompanyXilio Therapeutics
- CompanyCrossbow Therapeutics
- CompanyTango Therapeutics
Shares Samsara BioCapital, RA Capital Management.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
racap.com · 1
service.gov.uk · 1
A source that has moved or gone is reported by the weekly link check. /audit/